BLENREP (belantamab mafodotin-blmf) US Website

Explore information about BLENREP including Prescribing Information (including BOXED warning), Medication Guide and BLENREP REMS.

BLENREP REMS

The BLENREP REMS is a safety program that manages the risk of ocular toxicity from BLENREP. Find out more about the program on our website.

The DREAMM-2 Clinical Trial

Learn about DREAMM-2, which evaluated the efficacy and safety of belantamab mafodotin-blmf in patients with relapsed or refractory multiple myeloma including failure to prior treatment with an anti-CD38 antibody.

Materials for Treating Physicians

  • BLENREP REMS Fact Sheet

    BLENREP-REMS-Factsheet-Small
    Learn more about BLENREP REMS (Risk Evaluation and Mitigation Strategy), a safety program that manages the risk of ocular toxicity from BLENREP. Prescribers must be certified with the program by enrolling and completing training in the BLENREP REMS.
    Read more »

  • BLENREP Prescribing Information

    BLENREP-Prescribing-Information-Small
    _
    Read more »

  • Ophthalmic Support Services

    Ophthalmic-Support-Services-Small
    Together with GSK Oncology (TwGO) offers Ophthalmic Support Services to patients enrolled in the program to assist patients with corneal event management: including insurance verification, finding an eye care professional, appointment scheduling and reminders.
    Read more »

Patient Materials

  • Appointment Tracker

    Appointment-Tracker-Small
    This appointment tracker will help patients manage appointments with their hematologist/oncologist, eye care visits, and infusions.
    Read more »

  • Care Team Contact Information Card

    Care-Team-Contact-Information-Card-Small
    This wallet card will allow patients to carry medical and emergency contact information with them at all times. To be shown to HCPs during office visits and emergency room visits.
    Read more »